Cargando…
Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
Selexipag is an oral prostacyclin receptor agonist; it was recently approved for use in adults with pulmonary arterial hypertension. The safety and efficacy of selexipag has not yet been determined in the pediatric population. We describe short-term hemodynamic and clinical data with selexipag thera...
Autores principales: | Rothman, Abraham, Cruz, Gabriel, Evans, William N., Restrepo, Humberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026823/ https://www.ncbi.nlm.nih.gov/pubmed/32110381 http://dx.doi.org/10.1177/2045894019876545 |
Ejemplares similares
-
Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022) -
Selexipag for pulmonary arterial hypertension
Publicado: (2021) -
Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022) -
Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019) -
CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension
por: Rothman, Abraham, et al.
Publicado: (2023)